Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway

References

• Xue R, Gui D, Zheng L, et al. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J Diabetes Res. 2017;2017:1–15. doi:10.1155/2017/1839809.
   Web of Science ®Google Scholar
• Gheith O, Farouk N, Nampoory N, et al. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5(1):49–56.
   PubMedGoogle Scholar
• Burrows NR, Hora I, Geiss LS, et al. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed Diabetes – United States and Puerto Rico, 2000–2014. MMWR Morb Mortal Wkly Rep. 2017;66(43):1165–1170. doi:10.15585/mmwr.mm6643a2.
   PubMed Web of Science ®Google Scholar
• Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–906. doi:10.1056/NEJMc1602469.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. doi:10.2215/CJN.11491116.
   PubMed Web of Science ®Google Scholar
• Kawanami D, Matoba K, Utsunomiya K. Signaling pathways in diabetic nephropathy. Histol Histopathol. 2016;31(10):1059–1067. doi:10.14670/HH-11-777.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int Suppl. 1996;54: 10–13.
   Google Scholar
• Bagby SP. Diabetic nephropathy and proximal tubule ROS: challenging our glomerulocentricity. Kidney Int. 2007;71(12):1199–1202. doi:10.1038/sj.ki.5002286.
   PubMed Web of Science ®Google Scholar
• Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol. 2003;14(2):530–537. doi:10.1097/01.asn.0000051700.07403.27.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21(11):1819–1834. doi:10.1681/ASN.2010080793.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen DQ, Wang M, et al. Role of RAS/wnt/β-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chem Biol Interact. 2017;273:56–72. doi:10.1016/j.cbi.2017.05.025.
   PubMed Web of Science ®Google Scholar
• Feng YL, Chen DQ, Vaziri ND, et al. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev. 2020;40(1):54–78. doi:10.1002/med.21596.
   PubMed Web of Science ®Google Scholar
• Schunk SJ, Floege J, Fliser D, et al. WNT-β-catenin signalling – a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17(3):172–184. doi:10.1038/s41581-020-00343-w.
   PubMed Web of Science ®Google Scholar
• Pan B, Zhang H, Hong Y, et al. Indoleamine-2,3-dioxygenase activates Wnt/β-catenin inducing kidney fibrosis after acute kidney injury. Gerontology. 2021;67(5):611–619. doi:10.1159/000515041.
   PubMed Web of Science ®Google Scholar
• Zhou S, Wu Q, Lin X, et al. Cannabinoid receptor type 2 promotes kidney fibrosis through orchestrating β-catenin signaling. Kidney Int. 2021;99(2):364–381. doi:10.1016/j.kint.2020.09.025.
   PubMed Web of Science ®Google Scholar
• Xiao X, He Z, Cao W, et al. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/akt signaling pathways. Int J Oncol. 2016;48(6):2608–2618. doi:10.3892/ijo.2016.3488.
   PubMed Web of Science ®Google Scholar
• Liu QQ, Chen K, Ye Q, et al. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing wnt/β-catenin signaling pathway. Cancer Cell Int. 2016;16(1):57. doi:10.1186/s12935-016-0336-z.
   PubMedGoogle Scholar
• Xu J, Wold EA, Ding Y, et al. Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection. Molecules. 2018;23(2):474. doi:10.3390/molecules23020474.
   PubMed Web of Science ®Google Scholar
• Guo W, Zheng P, Zhang J, et al. Oridonin suppresses transplant rejection by depleting T cells from the periphery. Int Immunopharmacol. 2013;17(4):1148–1154. doi:10.1016/j.intimp.2013.10.023.
   PubMed Web of Science ®Google Scholar
• Liu QQ, Wang HL, Chen K, et al. Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B. J Dig Dis. 2016;17(2):104–112. doi:10.1111/1751-2980.12314.
   PubMed Web of Science ®Google Scholar
• Owona BA, Schluesener HJ. Molecular insight in the multifunctional effects of oridonin. Drugs R D. 2015;15(3):233–244. doi:10.1007/s40268-015-0102-z.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang L, Yang M, et al. Oridonin attenuates LPS-induced early pulmonary fibrosis by regulating impaired autophagy, oxidative stress, inflammation and EMT. Eur J Pharmacol. 2022;923:174931. doi:10.1016/j.ejphar.2022.174931.
   PubMed Web of Science ®Google Scholar
• Gao RF, Li X, Xiang HY, et al. The covalent NLRP3-inflammasome inhibitor oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol. 2021;90:107133. doi:10.1016/j.intimp.2020.107133.
   PubMed Web of Science ®Google Scholar
• Liu D, Qin H, Yang B, et al. Oridonin ameliorates carbon tetrachloride-induced liver fibrosis in mice through inhibition of the NLRP3 inflammasome. Drug Dev Res. 2020;81(4):526–533. doi:10.1002/ddr.21649.
   PubMed Web of Science ®Google Scholar
• Li J, Bao L, Zha D, et al. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways. Int Immunopharmacol. 2018;55:9–19. doi:10.1016/j.intimp.2017.11.040.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou Y, Sun Y, et al. Beneficial effects of oridonin on myocardial ischemia/reperfusion injury: insight gained by metabolomic approaches. Eur J Pharmacol. 2019;861:172587. doi:10.1016/j.ejphar.2019.172587.
   PubMed Web of Science ®Google Scholar
• de Boer IH. A new chapter for diabetic kidney disease. N Engl J Med. 2017;377(9):885–887. doi:10.1056/NEJMe1708949.
   PubMed Web of Science ®Google Scholar
• Vaisar T, Durbin-Johnson B, Whitlock K, et al. Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes. Diabetes Care. 2018;42(6):1155–2369. doi:10.2337/dc18-0699.
   Web of Science ®Google Scholar
• Zhou D, Liu Y. Renal fibrosis in 2015: understanding the mechanisms of kidney fibrosis. Nat Rev Nephrol. 2016;12(2):68–70. doi:10.1038/nrneph.2015.215.
   PubMed Web of Science ®Google Scholar
• Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31(1):99–109. doi:10.1016/0092-8674(82)90409-3.
   PubMed Web of Science ®Google Scholar
• Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985–999. doi:10.1016/j.cell.2017.05.016.
   PubMed Web of Science ®Google Scholar
• Ren X, Zhu R, Liu G, et al. Effect of sitagliptin on tubulointerstitial Wnt/β-catenin signalling in diabetic nephropathy. Nephrology. 2019;24(11):1189–1197. doi:10.1111/nep.13641.
   PubMed Web of Science ®Google Scholar
• He L, Li Q, Du C, et al. Glis2 inhibits the epithelial-mesenchymal transition and apoptosis of renal tubule cells by regulating the β-catenin signalling pathway in diabetic kidney disease. Biochem Biophys Res Commun. 2022;607:73–80. doi:10.1016/j.bbrc.2022.03.111.
   PubMed Web of Science ®Google Scholar
• Zhang RD, Shi M. Occurrence and development of diabetic nephropathy caused by CD63 by inhibiting Wnt-β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(1):284–294. doi:10.26355/eurrev_202001_19923.
   PubMed Web of Science ®Google Scholar
• Wang E, Wang L, Ding R, et al. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Pharmacol Res. 2020;157:104831. doi:10.1016/j.phrs.2020.104831.
   PubMed Web of Science ®Google Scholar
• Xiang X, Cai HD, Su SL, et al. Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/β-catenin and TGF-β signaling inhibition. Pharmacol Res. 2019;139:26–40. doi:10.1016/j.phrs.2018.10.030.
   PubMed Web of Science ®Google Scholar
• Dai X, Su S, Cai H, et al. Protective effects of total glycoside from rehmannia glutinosa leaves on diabetic nephropathy rats via regulating the metabolic profiling and modulating the TGF-β1 and Wnt/β-catenin signaling pathway. Front Pharmacol. 2018;9:1012. doi:10.3389/fphar.2018.01012.
   PubMed Web of Science ®Google Scholar
• Zhu S, Hou S, Lu Y, et al. USP36-mediated deubiquitination of DOCK4 contributes to the diabetic renal tubular epithelial cell injury via wnt/β-catenin signaling pathway. Front Cell Dev Biol. 2021;9:638477. doi:10.3389/fcell.2021.638477.
   PubMed Web of Science ®Google Scholar
• Liang J, Wang W, Wei L, et al. Oridonin inhibits growth and induces apoptosis of human neurocytoma cells via the Wnt/β-catenin pathway. Oncol Lett. 2018;16(3):3333–3340. doi:10.3892/ol.2018.8977.
   PubMed Web of Science ®Google Scholar
• Bu H, Liu D, Cui J, et al. Wnt/β-catenin signaling pathway is involved in induction of apoptosis by oridonin in Colon cancer COLO205 cells. Transl Cancer Res. 2019;8(5):1782–1794. doi:10.21037/tcr.2019.08.25.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu YZ, Zhang RX, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 2014;45(2):795–803. doi:10.3892/ijo.2014.2456.
   PubMed Web of Science ®Google Scholar
• Wang YN, Liu HJ, Ren LL, et al. Shenkang injection improves chronic kidney disease by inhibiting multiple renin-angiotensin system genes by blocking the Wnt/β-catenin signalling pathway. Front Pharmacol. 2022;13:964370. doi:10.3389/fphar.2022.964370.
   PubMed Web of Science ®Google Scholar
• Wang YN, Miao H, Hua MR, et al. Moshen granule ameliorates membranous nephropathy by blocking intrarenal renin-angiotensin system signalling via the Wnt1/β-catenin pathway. Phytomedicine. 2023;114:154763. doi:10.1016/j.phymed.2023.154763.
   PubMed Web of Science ®Google Scholar
• Gao Y, Dai H, Zhang N, et al. The ameliorative effect of mahuang fuzi and shenzhuo decoction on membranous nephropathy of rodent model is associated with autophagy and wnt/β-catenin pathway. Front Pharmacol. 2022;13:820130. doi:10.3389/fphar.2022.820130.
   PubMed Web of Science ®Google Scholar